TWI890704B - 用於失智症之glp-1受體促效劑 - Google Patents
用於失智症之glp-1受體促效劑Info
- Publication number
- TWI890704B TWI890704B TW109138851A TW109138851A TWI890704B TW I890704 B TWI890704 B TW I890704B TW 109138851 A TW109138851 A TW 109138851A TW 109138851 A TW109138851 A TW 109138851A TW I890704 B TWI890704 B TW I890704B
- Authority
- TW
- Taiwan
- Prior art keywords
- glp
- dementia
- receptor agonist
- administered
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207501.8 | 2019-11-06 | ||
| EP19207501 | 2019-11-06 | ||
| EP20186623 | 2020-07-20 | ||
| EP20186623.3 | 2020-07-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202118509A TW202118509A (zh) | 2021-05-16 |
| TWI890704B true TWI890704B (zh) | 2025-07-21 |
Family
ID=73172681
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109138851A TWI890704B (zh) | 2019-11-06 | 2020-11-06 | 用於失智症之glp-1受體促效劑 |
| TW114103408A TWI923289B (zh) | 2019-11-06 | 2020-11-06 | 用於失智症之glp-1受體促效劑 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW114103408A TWI923289B (zh) | 2019-11-06 | 2020-11-06 | 用於失智症之glp-1受體促效劑 |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| US20230088005A1 (en) * | 2020-01-30 | 2023-03-23 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| EP4262873A4 (en) * | 2020-12-16 | 2024-12-11 | The Chinese University of Hong Kong | A method for reversing aging brain functional decline |
| CN118510545A (zh) | 2021-12-02 | 2024-08-16 | 哥本哈根大学 | 用于治疗神经退行性疾病的肽-药物缀合物 |
| CN120731085A (zh) * | 2023-03-02 | 2025-09-30 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| WO2026096637A1 (en) * | 2024-10-30 | 2026-05-07 | Tiziana Life Sciences Plc | Glp-1 agonists and foralumab combination therapies |
| CN120131965A (zh) * | 2025-04-10 | 2025-06-13 | 瓯江实验室 | Glp-1受体激动剂治疗阿尔茨海默病的用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016198624A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| AU3357800A (en) | 1999-02-05 | 2000-08-25 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
| AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| EP1411968B1 (en) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| MX2008001468A (es) | 2005-06-30 | 2008-04-07 | Sod Conseils Rech Applic | Composiciones farmaceuticas del peptido similar al glucagon-1. |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| EP2066337A2 (en) | 2006-08-04 | 2009-06-10 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
| MX2009002121A (es) | 2006-09-07 | 2009-05-20 | Hoffmann La Roche | Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico. |
| US8756102B2 (en) * | 2009-11-06 | 2014-06-17 | Edatanetworks Inc. | Method, system, and computer program for attracting local and regional businesses to an automated cause marketing environment |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| HUE049152T2 (hu) * | 2012-07-01 | 2020-09-28 | Novo Nordisk As | Hosszantartó hatású GLP-1 peptidek alkalmazása |
| WO2015155151A1 (en) | 2014-04-07 | 2015-10-15 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
| AU2016379403B2 (en) * | 2015-12-23 | 2020-03-12 | The Johns Hopkins University | Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions |
| US20190142905A1 (en) | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| IL294521A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
-
2020
- 2020-11-05 CA CA3154744A patent/CA3154744A1/en active Pending
- 2020-11-05 AU AU2020377469A patent/AU2020377469A1/en active Pending
- 2020-11-05 HU HUE20803489A patent/HUE067514T2/hu unknown
- 2020-11-05 MA MA57599A patent/MA57599B1/fr unknown
- 2020-11-05 KR KR1020227015440A patent/KR20220110731A/ko active Pending
- 2020-11-05 PH PH1/2022/550842A patent/PH12022550842A1/en unknown
- 2020-11-05 RS RS20240863A patent/RS65780B1/sr unknown
- 2020-11-05 EP EP20803489.2A patent/EP4054620B1/en active Active
- 2020-11-05 BR BR112022007721A patent/BR112022007721A2/pt unknown
- 2020-11-05 ES ES20803489T patent/ES2984177T3/es active Active
- 2020-11-05 PL PL20803489.2T patent/PL4054620T3/pl unknown
- 2020-11-05 IL IL291876A patent/IL291876A/en unknown
- 2020-11-05 HR HRP20241052TT patent/HRP20241052T1/hr unknown
- 2020-11-05 JP JP2022521146A patent/JP7670698B2/ja active Active
- 2020-11-05 MX MX2022004779A patent/MX2022004779A/es unknown
- 2020-11-05 EP EP24175772.3A patent/EP4414031A3/en active Pending
- 2020-11-05 WO PCT/EP2020/081087 patent/WO2021089678A1/en not_active Ceased
- 2020-11-05 CN CN202080076976.0A patent/CN114728042A/zh active Pending
- 2020-11-06 TW TW109138851A patent/TWI890704B/zh active
- 2020-11-06 TW TW114103408A patent/TWI923289B/zh active
-
2022
- 2022-05-04 US US17/736,116 patent/US20220280612A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,485 patent/US20230302094A1/en not_active Abandoned
-
2024
- 2024-01-30 US US18/426,412 patent/US20240207364A1/en active Pending
- 2024-12-04 JP JP2024211204A patent/JP2025027130A/ja active Pending
- 2024-12-12 US US18/979,068 patent/US12539326B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016198624A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
Non-Patent Citations (1)
| Title |
|---|
| 期刊 Liping Zhang Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model Neuropeptides 71 July 2018 1-11 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RS65780B1 (sr) | 2024-08-30 |
| WO2021089678A1 (en) | 2021-05-14 |
| EP4054620A1 (en) | 2022-09-14 |
| EP4414031A3 (en) | 2025-02-05 |
| TW202519256A (zh) | 2025-05-16 |
| ES2984177T3 (es) | 2024-10-29 |
| MA57599B1 (fr) | 2024-06-28 |
| MX2022004779A (es) | 2022-06-14 |
| TWI923289B (zh) | 2026-04-21 |
| JP2023500032A (ja) | 2023-01-04 |
| IL291876A (en) | 2022-06-01 |
| EP4054620C0 (en) | 2024-05-29 |
| BR112022007721A2 (pt) | 2022-07-12 |
| KR20220110731A (ko) | 2022-08-09 |
| PL4054620T3 (pl) | 2024-10-14 |
| CA3154744A1 (en) | 2021-05-14 |
| EP4414031A2 (en) | 2024-08-14 |
| TW202118509A (zh) | 2021-05-16 |
| US20220280612A1 (en) | 2022-09-08 |
| EP4054620B1 (en) | 2024-05-29 |
| US12539326B2 (en) | 2026-02-03 |
| US20240207364A1 (en) | 2024-06-27 |
| HRP20241052T1 (hr) | 2024-11-08 |
| US20250099549A1 (en) | 2025-03-27 |
| JP7670698B2 (ja) | 2025-04-30 |
| PH12022550842A1 (en) | 2023-10-09 |
| CN114728042A (zh) | 2022-07-08 |
| US20230302094A1 (en) | 2023-09-28 |
| AU2020377469A1 (en) | 2022-04-28 |
| HUE067514T2 (hu) | 2024-10-28 |
| JP2025027130A (ja) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12539326B2 (en) | Methods for treating Alzheimer's disease using semaglutide | |
| US20250082651A1 (en) | Ganaxolone for use in treating genetic epileptic disorders | |
| JP6561136B2 (ja) | 勃起機能不全を治療又は改善するための方法及びsglt2阻害薬を含む医薬組成物 | |
| US20200338040A1 (en) | Methods for treating alzheimer's disease and related disorders | |
| US10463655B2 (en) | Method of treatment with tradipitant | |
| US20250152672A1 (en) | Semaglutide for use in medicine | |
| US20230098944A1 (en) | Method of decreasing amyloid beta monomer levels in patients with cognitive decline | |
| BR112019023557A2 (pt) | Composição farmacêutica compreendendo inibidor de pde9 | |
| AU763273B2 (en) | Analgesic regimen | |
| EA052078B1 (ru) | Агонисты рецептора glp-1 при лечении деменции | |
| EA046973B1 (ru) | Агонисты рецептора glp-1 при лечении деменции | |
| HK40075453A (en) | Semaglutide in the treatment of alzheimer's dementia | |
| US20200038414A1 (en) | Methods of treating constipation using aminosterol compositions | |
| US11213494B2 (en) | Compositions and methods for the treatment of pervasive development disorders | |
| EP4695225A1 (en) | Treatment for amyotrophic lateral sclerosis (als) | |
| HK1155659B (en) | Pharmaceutical composition for treatment of fibromyalgia | |
| HK1155659A1 (en) | Pharmaceutical composition for treatment of fibromyalgia |